for Cancer

ACTOnco-logo

ACTOnco™ is the most efficient and comprehensive platform that supports the study of cancer pathway for novel biomarker discovery, molecular target discovery and patient stratification. The platform can also be used evaluate the mutational status for approved targeted anticancer drugs and clinical agents.

  • 1.75 millions of bases, with 2,818 COSMIC cancer hotspots, are covered.
  • With 16,000 amplicons, all coding regions of 409 genes governing 12 important cancer signaling pathways are covered.
    • Cell cycle (e.g. CDK4, CCNE1, CDKN2A), RAS (e.g. KRAS, NRAS, BRAF), PI3K (e.g. AKT1, PTEN, PIK3CA), MAPK (e.g. MAPK1, CEBPA, SRC), and TGF-β (e.g. ACVR2, SMAD4, TGFBR2) pathways.
    • NOTCH (e.g. NOTCH1, EP300, CREBBP), APC (e.g. CDH1, GNA11, CTNNB1), HH (e.g. SMO, PTCH1, STK36), 78 important transcription factors, (e.g. NFKB1, GATA2, MYC), 28 chromatin remodeling genes (e.g. ARID1A, MEN1, SMARCB1), and 30 genes for DNA repairing and chromosome stability (e.g. ERCC1, MLH1, CHEK1).
  • Actionable drugs including 36 US FDA approved cancer targeted therapies and 79 investigational drugs.

Our report generating engine utilizes standard reference database, in-house sequencing database, and manually curated drug-gene interaction database to achieve a comprehensive and therapeutically-relevant interpretation. Results are presented in a custom-designed graphic format to deliver intuitive and publication-ready reports.

Specific

Service ACTOnco™
Targets Coding exons of 409 oncogenes and tumor suppressor genes
COSMIC Mutation 2,818 COSMIC mutations
Sequencing Mean Depth >1,000x
Input DNA Required 100 ng
Starting Materials Frozen tissue, FFPE tissue, core needle biopsy tissue, CTC, ctDNA, and blood
Report Sample report and statistical data

Results and Statistical Analysis

Clinical Research Data:

  • Individual sample report
    1. Sequencing QC report
    2. Variant alteration description
    3. Copy number variation
  • Project report
    1. Mutation pattern by project cohort
    2. Distribution of sequence variants
    3. Distribution of non-synonymous mutation by sample
    4. Signaling pathway involving variants
    5. Comparing mutation spectrum of 5 selected genes with TCGA data

Statistical Results:

  • Sample > 40
    1. Group-wise variant comparison
  • Sample > 40, survival data available
    1. Kaplan-Meier analysis (including log-rank test)
    2. Cox Regression analysis (including hazard ratio)

Order Service

Download